fluorodeoxyglucose f18 has been researched along with Tauopathies in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Castillo, AM; Graff-Radford, J; Jack, CR; Knopman, DS; Lowe, VJ; Mielke, MM; Petersen, RC; Ramanan, VK; Vemuri, P | 1 |
| Hsiao, IT; Jang, MK; Lin, KJ; Tai, CY; Weng, CC; Wu, MF; Yang, QF; Yao, CH; Yen, TC | 1 |
| Bischof, GN; Drzezga, A; Endepols, H; van Eimeren, T | 1 |
| Drubach, DA; Graff-Radford, J; Jack, CR; Josephs, KA; Lowe, VJ; Machulda, MM; Martin, PR; Reid, RI; Schwarz, CG; Senjem, ML; Sintini, I; Spychalla, AJ; Whitwell, JL | 1 |
| Centonze, D; Chiaravalloti, A; Izzi, F; Liguori, C; Mercuri, NB; Modugno, N; Olivola, E; Pierantozzi, M; Placidi, F; Ruffini, R; Schillaci, O; Stefani, A | 1 |
| Amtage, F; Bormann, T; Frings, L; Hellwig, S; Kreft, A; Meyer, PT; Spehl, TS; Tüscher, O; Weiller, C | 1 |
| Botha, H; Dickson, DW; Josephs, KA; Lowe, V; Whitwell, JL; Zalewski, N | 1 |
| Baron, T; Billard, T; Bouillot, C; Chauveau, F; Lancelot, S; Levigoureux, E; Verchere, J; Verdurand, M; Zimmer, L | 1 |
| Aldea, P; Ances, BM; Benzinger, TL; Cairns, NJ; Christensen, J; Fagan, AM; Friedrichsen, K; McConathy, J; Morris, JC; Su, Y; Wang, L | 1 |
| Cummins, G; Lynch, T; Magennis, B; Murray, B; O'Dowd, S; Roberts, K | 1 |
| Bäuml, J; Diehl-Schmid, J; Drzezga, A; Eisele, T; Förstl, H; Ibach, B; Kurz, A; Laws, SM; Perneczky, R; Riemenschneider, M | 1 |
1 review(s) available for fluorodeoxyglucose f18 and Tauopathies
| Article | Year |
|---|---|
Tau-imaging in neurodegeneration.
Topics: Animals; Brain; Fluorodeoxyglucose F18; Humans; Neurodegenerative Diseases; Positron Emission Tomography Computed Tomography; Protein Binding; tau Proteins; Tauopathies | 2017 |
10 other study(ies) available for fluorodeoxyglucose f18 and Tauopathies
| Article | Year |
|---|---|
Association of Apolipoprotein E ɛ4, Educational Level, and Sex With Tau Deposition and Tau-Mediated Metabolic Dysfunction in Older Adults.
Topics: Aged; Aged, 80 and over; Amyloid beta-Peptides; Apolipoprotein E4; Biomarkers; Educational Status; Female; Fluorodeoxyglucose F18; Humans; Male; Minnesota; Positron-Emission Tomography; Radiopharmaceuticals; Sex Factors; tau Proteins; Tauopathies | 2019 |
Characterization of
Topics: Animals; Benzothiazoles; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Immunohistochemistry; Mice; Mice, Transgenic; Molecular Structure; Positron-Emission Tomography; Radioactive Tracers; Radiochemistry; tau Proteins; Tauopathies | 2020 |
Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anisotropy; Aphasia, Primary Progressive; Atrophy; Brain Mapping; Diffusion Tensor Imaging; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neuroimaging; Positron-Emission Tomography; Radiopharmaceuticals; Tauopathies; White Matter | 2019 |
Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and α-synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study.
Topics: Aged; Brain; Female; Fluorodeoxyglucose F18; Glucose; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; REM Sleep Behavior Disorder; Synucleinopathies; Tauopathies | 2019 |
Neural correlates of cognitive dysfunction in Lewy body diseases and tauopathies: combined assessment with FDG-PET and the CERAD test battery.
Topics: Aged; Cognition Disorders; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Learning; Lewy Body Disease; Male; Neuropsychological Tests; Positron-Emission Tomography; Radiopharmaceuticals; Semantics; Tauopathies | 2013 |
FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants.
Topics: Age of Onset; Aged; Aged, 80 and over; Autopsy; Brain Chemistry; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuroglia; Positron-Emission Tomography; Radiopharmaceuticals; Supranuclear Palsy, Progressive; Tauopathies | 2014 |
Binding of the PET radiotracer [¹⁸F]BF227 does not reflect the presence of alpha-synuclein aggregates in transgenic mice.
Topics: alpha-Synuclein; Animals; Benzoxazoles; Brain Stem; Disease Models, Animal; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Positron-Emission Tomography; Radioligand Assay; Tauopathies; Thalamus; Thiazoles | 2014 |
Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Carbolines; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Outcome Assessment, Health Care; Peptide Fragments; Positron-Emission Tomography; Severity of Illness Index; tau Proteins; Tauopathies | 2016 |
Pallidopontonigral degeneration: a deceptive familial tauopathy.
Topics: Adult; Female; Fluorodeoxyglucose F18; Globus Pallidus; Humans; Positron-Emission Tomography; Substantia Nigra; Tauopathies | 2012 |
Association of the tau haplotype H2 with age at onset and functional alterations of glucose utilization in frontotemporal dementia.
Topics: Age Factors; Age of Onset; Aged; Aged, 80 and over; Cerebral Cortex; Dementia; Fluorodeoxyglucose F18; Frontal Lobe; Gene Frequency; Genetic Predisposition to Disease; Genotype; Glucose; Haplotypes; Humans; Male; Middle Aged; Positron-Emission Tomography; Risk Factors; tau Proteins; Tauopathies | 2007 |